MLTX (MoonLake Immunotherapeutics) Debt-to-EBITDA : -0.38 (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

MLTX MoonLake Immunotherapeutics MLTX
28 GF Score
Price $19.01
! 3 Warning Signs
View Full Analysis

What is MoonLake Immunotherapeutics Debt-to-EBITDA?

MoonLake Immunotherapeutics MLTX -4.81% 28 Debt-to-EBITDA is -0.38 as of Mar. 2026. GuruFocus rates MLTX with a GF Score™ of 28/100. The stock has 3 warning signs investors should review. Among 291 Biotechnology companies, MoonLake Immunotherapeutics ranks worse than 343642.27% on this metric.

Debt-to-EBITDA measures a company's ability to pay off its debt.

MoonLake Immunotherapeutics's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2026 was $0.92 Mil. MoonLake Immunotherapeutics's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2026 was $99.88 Mil. MoonLake Immunotherapeutics's annualized EBITDA for the quarter that ended in Mar. 2026 was $-263.88 Mil. MoonLake Immunotherapeutics's annualized Debt-to-EBITDA for the quarter that ended in Mar. 2026 was -0.38.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for MoonLake Immunotherapeutics's Debt-to-EBITDA or its related term are showing as below:

MLTX' s Debt-to-EBITDA Range Over the Past 10 Years
Min: -0.41   Med: -0.05   Max: 0
Current: -0.41
MLTX's Debt-to-EBITDA is ranked worse than
100% of 291 companies
in the Biotechnology industry
Industry Median: 1.14 vs MLTX: -0.41

MoonLake Immunotherapeutics  (NAS:MLTX) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.

Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

MoonLake Immunotherapeutics Debt-to-EBITDA Related Terms

MoonLake Immunotherapeutics Debt-to-EBITDA Historical Data

* Premium members only.

The historical data trend for MoonLake Immunotherapeutics's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

MoonLake Immunotherapeutics Debt-to-EBITDA Chart

MoonLake Immunotherapeutics Annual Data
Trend Dec21 Dec22 Dec23 Dec24 Dec25
Debt-to-EBITDA
N/A -0.00 -0.09 -0.02 -0.34

MoonLake Immunotherapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Debt-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.47 -0.36 -0.28 -0.32 -0.38

MLTX vs FTRE, SEPN, URGN: Debt-to-EBITDA Comparison

For the Biotechnology subindustry, MoonLake Immunotherapeutics's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

MoonLake Immunotherapeutics Debt-to-EBITDA vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, MoonLake Immunotherapeutics's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where MoonLake Immunotherapeutics's Debt-to-EBITDA falls into.


MLTX
28GF Score
MoonLake Immunotherapeutics MLTX
Debt-to-EBITDA is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

MoonLake Immunotherapeutics Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

MoonLake Immunotherapeutics's Debt-to-EBITDA for the fiscal year that ended in Dec. 2025 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(1.234 + 74.474) / -219.846
=-0.34

MoonLake Immunotherapeutics's annualized Debt-to-EBITDA for the quarter that ended in Mar. 2026 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(0.92 + 99.883) / -263.884
=-0.38

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is four times the quarterly (Mar. 2026) EBITDA data.

Frequently Asked Questions Learn more about Debt-to-EBITDA →
What does a Debt-to-EBITDA of -0.38 mean?
MoonLake Immunotherapeutics (MLTX) has a Debt-to-EBITDA of -0.38 as of Mar. 2026. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on MoonLake Immunotherapeutics. According to the industry distribution chart, MoonLake Immunotherapeutics ranks #999999 out of 291 companies in the Biotechnology industry.
Is MoonLake Immunotherapeutics' Debt-to-EBITDA too high?
MoonLake Immunotherapeutics' current Debt-to-EBITDA is -0.38. Based on the distribution chart, MoonLake Immunotherapeutics ranks #999999 out of 291 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, MoonLake Immunotherapeutics has a GF Score™ of 28/100, reflecting its overall financial health beyond just this single metric.
How does MoonLake Immunotherapeutics' Debt-to-EBITDA compare to FTRE and SEPN?
According to the Biotechnology industry distribution chart, MoonLake Immunotherapeutics ranks #999999 out of 291 companies for Debt-to-EBITDA. This places MoonLake Immunotherapeutics in the lower half of its industry. The industry median Debt-to-EBITDA is 1.14. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-EBITDA for a Biotechnology company?
The median Debt-to-EBITDA among Biotechnology companies is 1.14, based on 291 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-EBITDA mean?
A high Debt-to-EBITDA can signal that a stock is expensive relative to its fundamentals. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on MoonLake Immunotherapeutics. For the Biotechnology industry, the median Debt-to-EBITDA is 1.14 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. MoonLake Immunotherapeutics's current Debt-to-EBITDA is -0.38. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is MoonLake Immunotherapeutics stock overvalued right now?
MoonLake Immunotherapeutics (MLTX) has a current Debt-to-EBITDA of -0.38. The current Debt-to-EBITDA is -0.38. MoonLake Immunotherapeutics' overall GF Score™ is 28/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-EBITDA calculated?
Debt-to-EBITDA is calculated from a company's financial statements. For MoonLake Immunotherapeutics (MLTX), the current Debt-to-EBITDA is -0.38 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

MoonLake Immunotherapeutics Business Description

Address Dorfstrasse 29, Zug, CHE, 6300
MoonLake Immunotherapeutics is a clinical-stage biotechnology company advancing therapies to address unmet needs in inflammatory skin and joint diseases. The company is focused on the development of SLK, a novel tri-specific IL-17A and IL-17F inhibiting Nanobody that has the potential, based on response levels seen in clinical trials, to drive disease modification in dermatology and rheumatology patients. It is currently developing SLK in inflammatory diseases in dermatology and rheumatology where the pathophysiology is known to be driven by IL-17A and IL-17F.
28GF Score

Get the complete analysis for MLTX

Debt-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$19.01
Price